The study met its primary endpoint, showing a statistically significant and clinically meaningful improvement in progression-free survival
Its a major breakthrough for women’s ovarian cancer care in Europe
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Subscribe To Our Newsletter & Stay Updated
